Australia Pharmaceuticals and Healthcare Industry Update Quarter 3 2012
$ 1 088
- May 2013
- by Business Monitor International
- 117
Includes 3 FREE quarterly updates
BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceutical
investors, given its ageing and generally affluent population. Importantly, the government is implementing
cost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers will stand to
benefit from the patented to generic drug switch. However, given that generic costs is higher in Australia as
compared to other developed countries, a downside risk to the view is the lack of generic substitution, given
no apparent benefits to patients.
Headline Expenditure Projections
• Pharmaceuticals: AUD13.47bn (US$13.95bn) in 2012 to AUD13.95bn (US$13.94bn) in 2013; +3.6%
in local currency terms and 0.0% in US dollar terms, due to exchange rate fluctuations. Forecast is
broadly in line with our Q213 forecast.
• Healthcare: AUD135.8bn (US$140.6bn) in 2012 to AUD141.8bn (US$141.8bn) in 2013; +4.4% in local
currency terms and +0.8% in US dollar terms, due to exchange rate fluctuations. Forecast reflects
recipient of new market data, long term forecast was a slight downgrade compared to Q213 given the
lower health expenditure growth.
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Business Environment 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, 2009-2017 16
Healthcare Market Forecast 17
Table: Overall Healthcare Expenditure, 2009-2017 19
Table: Government Healthcare Expenditure, 2009-2017 20
Table: Private Healthcare Expenditure, 2009-2017 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Sales, 2009-2017 22
Patented Drug Market Forecast 22
Table: Patented Drug Sales, 2009-2017 23
Generic Drug Market Forecast 24
Table: Cost Of Selected Drugs Post-Price Disclosure 26
Table: Generic Drug Sales, 2009-2017 28
OTC Medicine Market Forecast 28
Table: OTC Medicine Sales, 2009-2017 29
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Exports, 2009-2017 30
Table: Pharmaceutical Imports, 2009-2017 31
Table: Pharmaceutical Trade Balance, 2009-2017 31
Other Healthcare Data 31
Key Risks To BMI's Forecast Scenario 32
Macroeconomic Forecasts 33
Signs Of Overheating Weigh On Infrastructure Investments 34
Weakness In Other Sectors Further Weighing Down Economy 35
Austerity Measures To Be Reversed 36
Table: Australia - Economic Activity 38
Industry Risk Reward Ratings 39
Asia Pacific Risk/Reward Ratings 39
Industry Risk Reward Ratings 43
Rewards 44
Country Rewards 44
Risks 45
Country Risk 46
Market Overview 47
Industry Trends And Developments 49
Table: Main Causes Of Death In Australia, 2010 50
Table: Percentage Of Children Immunised (December 31 2011) 51
Regulatory Development 52
Table: Summary Of TGA Reforms 53
Table: Historical PBS Co-Payments 63
Table: New PBS Formularies 69
Competitive Landscape 71
Table: Top-20 Pharmaceutical Suppliers By Value From Processed PBS Prescriptions (AUDmn), ending June 2012 75
Company Profile 76
Sigma 76
API 80
Alphapharm 83
Herron 86
CSL 89
Mayne 93
Sanofi 97
GSK 100
Merck & Co 104
Demographic Forecast 107
Table: Australia's Population By Age Group, 1990-2020 ('000) 108
Table: Australia's Population By Age Group, 1990-2020 (% of total) 109
Table: Australia's Key Population Ratios, 1990-2020 110
Table: Australia's Rural And Urban Population, 1990-2020 110
Glossary 111
Methodology 113
Methodology 113
Pharmaceutical Expenditure Forecast Model 113
Healthcare Expenditure Forecast Model 113
Notes On Methodology 114
Risk/Reward Ratings Methodology 115
Ratings Overview 116
Table: Pharmaceutical Risk/Reward Ratings Indicators 116
Indicator Weightings 117
Drug and Medication in Australia
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : Australia
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : Australia
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : Australia
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : Australia
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : Australia